Introduction
Veno-occlusive disease (VOD) of the liver is a common complication following the intensive conditioning regimens used in stem cell transplantation (SCT). This condition is characterised by painful haepatomegaly, jaundice, ascites and fluid retention leading to unexplained weight gain. The reported incidence is between 10 and 60%. A severe illness with high mortality secondary to multiorgan failure is the most advanced form of the disease seen. 1 Indeed, in severe VOD the mortality rate approaches 100% by day 100 post-SCT. 2 The pathology of VOD is complex. Recent studies have suggested that the primary site of toxic injury is sinusoidal endothelial cells. The destruction of these cells and their embolisation leads to obstruction of sinusoidal blood flow and subsequent hepatic necrosis. These observations have led to the suggestion of a new name for the condition: sinusoidal obstruction syndrome. 3 During this process, a procoagulant state is present, with low plasma levels of antithrombin III and protein C, consumption of factor VII, increased levels of plasminogen activator inhibitor-1 and increased levels of von-Willebrand factor multimers. 4, 5 Progressive injury with haepatocellular necrosis, fibrogenesis and vascular occlusion leads to hepatorenal syndrome, multiorgan failure and death.
The treatment of VOD is challenging. Heparin, lowmolecular weight heparin, prostaglandin E1 and pentoxifylline have no proven benefit and have been associated with haemorrhagic complications. 6 A prospective randomised open-label trial of ursodeoxycholic acid showed no effect on the incidence of VOD despite some improvement in transaminitis, severe graft-versus-host disease (GVHD) and survival. 7 Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine tissue, which has antithrombotic, thrombolytic, anti-inflammatory and antiischaemic properties. Early phase trials of defibrotide in the treatment of moderate to severe VOD have shown promising results with minimal attributable toxicity, encouraging complete response rates (36-50%) and consistent improvements in day þ 100 survival (at 30-60% versus 410% expected). [8] [9] [10] [11] [12] [13] Several studies have investigated various types of VOD prophylaxis. The role of prophylactic anticoagulation remains uncertain despite a recent meta-analysis.
14 Similarly, other agents have shown no definite reduction in the incidence of VOD. 13, 15, 16 To the best of our knowledge, only two published reports to date have detailed the use of prophylactic defibrotide in the allogeneic SCT population. The first study showed a significant reduction in VOD in 52 successive patients treated with prophylactic heparin and defibrotide when compared to historical controls who received heparin alone. 17 The second study used prophylactic defibrotide in conjunction with low-dose heparin in nine patients with malignant infantile osteopetrosis. We report a dramatic reduction in the VOD rate in this highrisk population. 18 Defibrotide prophylaxis was introduced in patients undergoing allogeneic SCT at the Royal Marsden Hospital in 2004. In contrast to the previous reports, heparin was not used routinely. We report a retrospective review of the incidence of VOD in 58 patients who received defibrotide prophylaxis during allogeneic SCT.
Methods

Patient population
The Royal Marsden computer database was used to identify adult patients who had received an allogeneic SCT from May 2004 to December 2005. This list was crossreferenced with the pharmacy database to ensure patients had received defibrotide prophylaxis. All patients had given verbal and written informed consent to receive defibrotide as part of the formal transplant consenting process. Patients who had not received defibrotide prophylaxis at standard doses were excluded from the analysis. The electronic hospital information system and clinical notes were reviewed with respect to clinical signs, treatment dose, investigations and risk factors. Patients were followed up for 100 days post transplantation.
SCT
All patients were admitted for conditioning regimens tailored to their underlying diagnosis, type of transplant and performance status. The majority of patients received campath 1-H (alemtuzumab) in vivo. Infection and GVHD prophylaxis were administered according to local guidelines. All patients received itraconazole as prophylaxis against fungal infection, which was commenced on day þ 1.
VOD prophylaxis
Patients received 5 mg/kg of defibrotide twice-daily i.v. (intravenously) from day þ 1 to þ 21 to a total dose of 10 mg/kg per day. Defibrotide was administered over 2 h by slow infusion and given twice daily. No patient received heparin or ursodeoxycholic acid as VOD prophylaxis.
Evaluation of VOD
All patients were assessed daily by clinical examination including weight and abdominal girth. Laboratory tests including liver function tests were undertaken daily. The Baltimore criteria were used to diagnose VOD: jaundice (bilirubin X34.2 mmol/l) and two or more of the following: haepatomegaly, right upper quadrant pain, ascites and unexplained weight gain (X5% above baseline weight). 19 If VOD was suspected, ultrasound of the liver with a Doppler test was performed.
Statistical analysis
Descriptive statistics were expressed as medians and percentages.
Results
Patient characteristics
Patient characteristics are shown in Table 1 and conditioning regimens in Table 2 . One patient received heparin treatment for a deep venous thrombosis (DVT) in addition to defibrotide therapy. Resolution of the DVT was confirmed on Doppler ultrasound imaging and the patient did not experience further thrombotic events or haemorrhagic complications.
Incidence of VOD
No patients met the Baltimore criteria for VOD and no patients died of suspected VOD within 100 days of transplantation. The transplant-related mortality (TRM) within 100 days was 5/58 (8.6%) of patients. Three patients died of bronchopneumonia, one of multiorgan failure secondary to sepsis and one of Escherichia coli septicaemia. VOD was not felt to have contributed to the deaths of any of these patients.
The dose of defibrotide was increased to 10 mg/kg four times daily i.v. in three patients in whom VOD formed part of differential diagnosis for deranged liver function tests but who did not meet the Baltimore criteria. The total dose was 40 mg/kg per day. One of these patients had a liver biopsy suggestive of mild VOD but also showed features consistent with GVHD and viral infection. The liver function of the other two patients improved after hepatotoxic drugs were stopped. All of these patients were alive at 100 days post transplant with no features of VOD. The characteristics of all patients with bilirubin 434 mmol/l within 100 days of transplantation are detailed in Table 3 . Drugs associated with hyperbilirubinaemia included azole antifungal agents and penicillin-based antimicrobials. These agents are known to cause derangement of liver function and jaundice from previous reports.
20,21,22
Side effect profile Patients tolerated defibrotide well and the drug did not have to be discontinued in any patient. There were no cases of haemorrhagic complications attributable to defibrotide.
Discussion
This study is, to the best of our knowledge, the first to report the use of defibrotide as VOD prophylaxis post allogeneic SCT without concurrent heparin administration. A total of 58 patients were included and none fulfilled the Baltimore criteria for VOD. The TRM within 100 days of SCT was favourable at 8.6% and VOD was not believed to have contributed to any of these deaths. These results support previous studies detailing a lower incidence of VOD following prophylactic defibrotide and heparin. 17, 18 Patients received standard doses of defibrotide and no haemorrhagic complications were reported. This finding is in keeping with previous reports suggesting that defibrotide can be administered with relative safety in this patient population. [8] [9] [10] [11] [12] [13] 17, 18 Hyperbilirubinaemia was noted to be common in post allogeneic SCT in our series. Twenty-nine patients (50%) had a bilirubin X34 mmol/l although they failed to meet the Baltimore criteria. In most of these patients, this abnormality could be explained by an alternative diagnosis including liver GVHD (24%) or infection (14%) or by haepatotoxic drugs (41%). It may be possible, however, that patients who received prophylactic defibrotide developed a form of subclinical VOD, which did not fulfil the standard diagnostic criteria and this therefore may reflect some form of favourable treatment effect.
There are many potential risk factors for VOD and the identification of fully matched controls for our study population would be difficult, particularly in view of recent changes in conditioning regimens. The high number of patients receiving reduced intensity regimens may partly explain the low incidence and severity of VOD but this group had several other high-risk factors. Eighteen out of 37 patients who underwent reduced intensity conditioning (49%) had received a previous transplant, 22/37 (59%) received a transplant from an unrelated donor and 8/37 (22%) had undergone prior abdominal irradiation. These features have all been associated with a higher incidence of VOD in previous reports. 1, 23, 24 In addition, our series reports no cases of VOD. This observation is in contrast to previous studies where, although the incidence and severity was less than in full intensity regimens, morbidity 25 and mortality 26 from VOD were still reported. In conclusion, this report suggests that the use of prophylactic defibrotide may reduce the incidence of VOD following allogeneic SCT. Our study also suggests that defibrotide may be effective without concurrent heparin administration. A randomised controlled trial with risk stratification is warranted to further define the benefits of defibrotide prophylaxis in this setting. Prophylactic defibrotide in allogeneic stem cell transplant
